DNLI
DNLI
NASDAQ · Biotechnology

Denali Therapeutics Inc

$20.47
+0.75 (+3.80%)
As of Sep 21, 9:59 PM ET ·
Analyst Consensus
Strong Buy
26
Analysts
High
Coverage
Buy 24 92%
Hold 2 8%
Sell 0 0%
Price Target
Analyst Price Target +274.0% upside
Low Target $56.04
Average Target $76.55
High Target $105.76
Current Price $20.47
Current
$20.47
Target
$76.55
$56.04 $76.55 avg $105.76
Scenario Analysis
Bear Case
$56.04
173.8%
Low target
Base Case
$76.55
+274.0%
Avg target
Bull Case
$105.76
+416.7%
High target
Risk/Reward
2.4x
Favorable
Price in Context
52-Week High
$27.30
-25.0% from high
52-Week Low
$12.58
+62.7% from low
50-Day SMA
$18.67
+9.6% vs SMA
200-Day SMA
$15.96
+28.3% vs SMA
RSI (14)
42.3
Neutral
Target vs 52W High
$76.55
+180.4% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -2.6%
AMGN
Amgen Inc
Hold 43 47% $190.87 -51.5%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +140.9%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -14.2%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -90.4%
MRNA
Moderna Inc
Hold 30 37% $149.45 -13.6%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -61.4%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -40.8%